Мы создали для вас Личный кабинет, чтобы вы могли быстрее покупать в следующий раз.Для активации воспользуйтесь ссылкой в письме, которое мы отправили на ваш Email
ОДЕССКАЯ РЕГИОНАЛЬНАЯ АКАДЕМИЯ НАУК /ОРАН/ проводит общественно - научную работу и является собственником многих патентов. Работы с микроэлементами, разработки технологий приготовления концентратов для искусственной минерализации воды, и многое другое.
For attention of the Science Department
Proposal for cooperation
DEAR COLLEAGUES! During the period from 1992 until 2017, a group of specialists, headed by me, of the Odessa Regional Academy of Sciences (ORAS) developed a drug under the patent name of "PELOVIT-R" (abbreviated "Pelovit") for the external use in the treatment of many acute and chronic diseases. At present, we are working on the application of the Pelovit for the treatment of the infantile cerebral palsy (CP).
1/. The Ministry of Public Health of Ukraine is extremely slow in considering the issue of clinical trials of the Pelovit for the treatment of the CP. During the time of our talks in the Ministry of Public Health of Ukraine, four Health Ministers were in office, while the issue of clinical trials of our drug for the treatment of the CP in newborns with the birth injury brain damage still remains open. So we ask the German specialists to accept our proposal to conduct a joint scientific research and clinical trials of the Pelovit for the treatment of the CP in newborns suffering from the birth injury brain damage and hypoxia. We are also ready to undertake international joint patenting of the new drug for the treatment of the CP in infants with the birth injury brain damage using the Pelovit as per our method.
2/. The Pelovit and the method of its production have been patented, as has been the trademark. We hope for a positive decision on your part regarding a joint scientific research and clinical trials of the Pelovit for the treatment of the CP along with joint international patenting of the new method of the treatment of the CP in infants and, what is the most important for us, for the decision to have all that funded by an interested party.
Ukraine and the ORAS have made their significant contribution. Now, with your consent to joint work, I propose to hold talks on the prospects for the scientific and economic cooperation.
In the world, there is no such method of the CP treatment or similar know-how, although there are syndrome-specific treatments and various options for kinesitherapy. By combining our expertise, we can obtain a much better result.
We can jointly develop and patent a new method for the treatment of the CP in infants.
Valentyn Ivanovych Degterenko, ORAS President, Doctor of Biology, PhD in Medicine
"THE BIOREACTOR MANUFACTURE OF A BREAST MILK SUBSTITUTE / also called the "outer space Ryazhenka" (a fermented milk product) or "antipsychotic agent" / FOR PREMATURE BABYS AND 1-2 YEARS OLD INFANTS".
Offered by the Odesa Regional Academy of Sciences (ORAS)
FERMENTED MILK DRINKS. UKRAINIAN PRODUCT SPECIFICATION 22447997-001-97. Agreed upon with the Deputy Surgeon General of Ukraine. Signed by the Minister of Health of Ukraine V.I. Romanenko / Letter No. 5.08.07/157 dd. June 6, 1995. Drawn up by the BALNEOLOG LLC on August 1, 1995.
Appendix No. 1 The production line for obtaining a biomass of living microorganisms BK 4 x 40 / 4 x 6.5 /. Product Specification BT 18 in 18 sheets.
Severe clinical forms of influenza, as evidenced by observations and the analysis of cases of death, although their share constitutes only tenths of a percentage point of those affected by the flu, are of particular importance, and they attract heightened public attention because they relate to at-risk children, pregnant women, the elderly and chronically ill persons. Consequently, a big mistake is a somewhat careless or light-minded utterance of the new Minister of Healthcare Mr. A.M. Kvitashvili that the death rate due to influenza during the latest epidemic constituted only a small percentage of those who fell ill. That erroneously reassuring and unemotional information is wrong for the simple reason that no one in a particular family can and does want to put up with a case of the child's or the elderly person's death from flu. If one prefers to go as far as such inhumane cynicism, it was easier to point out that many more people die from road accidents than from influenza.
Even the lack of funds in the budget of the Ministry of Healthcare of Ukraine for research on influenza and all the complicated nature of research on the flu-related problems should not be grounds for such appraisals. The progress of science cannot be stopped by such judgments...
After that introduction, the essence of the project of Odesa Regional Academy of Sciences (ORAS) is expounded:
«THE DEVELOPMENT OF ANTI-FLU HETEROLOGOUS BIVALENT Fab 2-FRAGMENTS OF ANTIBODIES FOR INTRAMUSCULAR AND INTRAVENOUS ADMINISTRATION TO TREAT PATIENTS WITH SEVERE FORMS OF INFLUENZA»
To that end, the ORAS possesses a technology for obtaining an anti-flu heterologous Fab fragment of antibodies developed way back in 1976 by V. I. Degtyarenko (Doctor of Biology), N. V. Miroshnichenko and A. V. Pertaya. That Fab fragment was meant for independent administration or that in combination with inhibitors of trypsin-like enzymes, and all that was detailed in a book titled «The Confession of a Ukrainian virologist, or How a New Method of Treating the Influenza was Discovered».
Novelties tend to pave the way under difficult conditions. The efficiency of bivalent heterologous Fab fragments of antibodies can be judged by a Fab 2-fragments-of-antibodies medication developed 30 years later than in Odessa by the «MICROGEN» Research and Production Company of the Russian Federation for the treatment of the absolutely fatal infection of rabies in humans.
In 1989 -1992, researchers of Odesa Regional Academy of Sciences (ORAS) developed A BIOTECHNOLOGY FOR OBTAINING ANTI-FLU AND ANTI-PARAFLU MEDICATIONS, VIZ. IMMUNE LACTO-GLOBULINS, from the immune cow colostrum whey / immune colostrum with the relevant documentation in the form of MRTU-42 (Inter-State Specifications-42) or Ukrainian Specifications attached, but unfortunately that documentation was never approved through any fault of those researchers. The project was formulated and presented as follows: «PROMISING NEW MEDICATIONS BASED ON ANTI-FLU AND ANTI-PARAFLU LACTO-GLOBULINS AS DIETARY SUPPLEMENTS (DSs) TO CHILDREN'S NUTRITION TO FIGHT INFLUENZA VIRUSES A2 AND C AND HUMAN PARAINFLUENZA VIRUS OF TYPE III».
For that purpose, large producers, i. e. cows of the Vladimir breed, were hyper-immunized with viral antigens / influenza viruses A2 and C, as well as type III PARAINFLUENZA using a unique propolis adjuvant. The immune colostrum of cows was collected during the first three days after calving. From that colostrum, the immune colostrum whey was obtained, from which, in turn, antiviral / anti-flu and anti-paraflu immune lacto-globulins were derived. There are no similar anti-flu drugs in the world used as dietary supplements to infant formulas.
The project is awaiting its foreign investors due to Ukraine's financial impotence and poverty.
Shown below are the photographs of specimens of medications, viz. antiviral immune colostrum lacto-globulins – dietary supplements.